DERM
Journey Medical Corporation NASDAQ$5.18
Mkt Cap $141.6M
52w Low $4.31
16.6% of range
52w High $9.55
50d MA $6.29
200d MA $7.36
P/E (TTM)
-11.0x
EV/EBITDA
-43.1x
P/B
4.0x
Debt/Equity
0.0x
ROE
-35.9%
P/FCF
-15.2x
RSI (14)
—
ATR (14)
—
Beta
1.04
50d MA
$6.29
200d MA
$7.36
Avg Volume
205.5K
About
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycl…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.06 | -0.04 | +33.3% | 6.83 | -13.6% | -30.0% | -32.9% | -35.7% | -31.3% | -32.1% | — |
| Nov 12, 2025 | AMC | -0.08 | -0.09 | -12.5% | 9.08 | -3.6% | -15.3% | -13.1% | -15.3% | -12.4% | -15.7% | — |
| Aug 12, 2025 | AMC | -0.07 | -0.16 | -128.6% | 8.54 | -13.2% | -15.1% | -15.0% | -18.6% | -18.0% | -17.2% | — |
| May 14, 2025 | AMC | -0.24 | -0.18 | +25.0% | 5.97 | +4.5% | +18.9% | +16.2% | +13.1% | +15.2% | +13.6% | — |
| Mar 26, 2025 | AMC | -0.22 | 0.08 | +136.4% | 6.14 | +1.0% | -3.6% | -0.5% | -3.9% | -2.8% | +1.6% | — |
| Nov 12, 2024 | AMC | -0.17 | -0.12 | +29.4% | 5.45 | +0.9% | -6.1% | -6.8% | -5.3% | -7.3% | -1.8% | — |
| Aug 12, 2024 | AMC | -0.15 | -0.17 | -13.3% | 4.22 | +3.3% | +14.2% | +12.8% | +8.1% | +5.0% | +8.3% | — |
| May 13, 2024 | AMC | -0.26 | -0.53 | -103.8% | 3.57 | -3.4% | +1.1% | +0.6% | +1.4% | -3.4% | -4.8% | — |
| Mar 21, 2024 | AMC | -0.08 | -0.12 | -50.0% | 3.82 | -8.4% | -13.6% | -23.6% | -3.4% | +1.8% | -3.7% | — |
| Nov 7, 2023 | AMC | -0.15 | 0.80 | +633.3% | 3.43 | +9.3% | +9.6% | +7.3% | +8.7% | +15.7% | +17.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.83 | $5.90 | -13.6% | -30.0% | -32.9% | -35.7% | -31.3% | -32.1% |
| Aug 13 | Lake Street | Maintains | Buy → Buy | — | $8.54 | $7.41 | -13.2% | -15.1% | -15.0% | -18.6% | -18.0% | -17.2% |
| Jul 30 | B. Riley Securities | Maintains | Buy → Buy | — | $7.59 | $7.64 | +0.7% | +0.0% | -3.2% | -7.9% | -5.9% | -5.0% |
| Sep 7 | B. Riley Securities | Maintains | Buy → Buy | — | $2.51 | $2.41 | -4.0% | +3.6% | +17.5% | +13.9% | +6.0% | +3.6% |
| Jul 12 | B. Riley Securities | Maintains | Buy → Buy | — | $2.36 | $2.49 | +5.5% | -12.3% | -25.0% | -24.2% | -23.3% | -21.6% |
| May 23 | B. Riley Securities | Maintains | Buy → Buy | — | $1.42 | $1.38 | -2.8% | -12.7% | -12.7% | -21.8% | -25.4% | -19.0% |
Recent Filings
8-K · 8.01
!! High
Journey Medical Corporation -- 8-K 8.01: Material Event / Announcement
Journey Medical's Emrosi secured expanded pharmacy benefit coverage, potentially increasing patient access and sales for its rosacea treatment.
Apr 21
8-K
Unknown — 8-K Filing
Journey Medical's earnings call today signals management confidence in discussing 2025 results, but investors should monitor whether revenue growth justifies the dermatology-focused commercial strategy amid competitive pressures.
Mar 25
Data updated apr 25, 2026 4:57am
· Source: massive.com